glp 1 pancreas Frontiers GLP-1 Therapies May Benefit MPN

with a mean increase of 8 points) and tirzepatide (SUMMIT), appears to be greater than what has been reported for other HFpEF trials investigating the benefits of angiotensin receptorneprilysin inhibitor (Paragon-HF), sodiumglucose cotransporter 2 inhibitors (EMPEROR-Preserved, DELIVER) and spironolactone (TOPCAT)

Scherer, P., Hill, J

[12] FEHB Plans: Zepbound on 2026 Formulary Kaiser FEHB and PSHB plans confirm Zepbound on 2026 formularies at Tier 3/4 (specialty tier)

Kim, H., Park, H., & Lee, S

Finerenone is effective at reducing cardiorenal events, but it doesnt treat diabetes

Glucagon-like peptide-1 does not mediate amylase release from AR42J cells